On September 20-21, 2016 Allison Dudley, Executive Director and David Flynn, Counsel to the Board attended an inter-governmental working meeting at the Food and Drug Administration to discuss the oversight of drug compounding and the relationship between the activities of the FDA and the states. The meeting provided an opportunity to discuss each state’s regulatory framework, recent FDA guidance documents, changes to the FDA’s inspection procedures, and information sharing challenges and opportunities.
More Latest News
August 29, 2019
Under a State of Emergency, a pharmacist, in his or her professional judgment, may be able to refill prescriptions early. Continue reading
August 23, 2019
The Quarterly Performance Report for the fourth quarter of the 2018-2019 fiscal year is now available online. Continue reading